Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Lurbinectedin by Jazz Pharmaceuticals for Neuroendocrine Carcinoma: Likelihood of Approval
Lurbinectedin is under clinical development by Jazz Pharmaceuticals and currently in Phase II for Neuroendocrine Carcinoma. According to GlobalData, Phase...
Lurbinectedin by Jazz Pharmaceuticals for Metastatic Transitional (Urothelial) Tract Cancer: Likelihood of Approval
Lurbinectedin is under clinical development by Jazz Pharmaceuticals and currently in Phase II for Metastatic Transitional (Urothelial) Tract Cancer. According...
Lurbinectedin by Jazz Pharmaceuticals for Metastatic Biliary Tract Cancer: Likelihood of Approval
Lurbinectedin is under clinical development by Jazz Pharmaceuticals and currently in Phase II for Metastatic Biliary Tract Cancer. According to...
Lurbinectedin by Jazz Pharmaceuticals for Triple-Negative Breast Cancer (TNBC): Likelihood of Approval
Lurbinectedin is under clinical development by Jazz Pharmaceuticals and currently in Phase II for Triple-Negative Breast Cancer (TNBC). According to...
Lurbinectedin by Jazz Pharmaceuticals for Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer): Likelihood of Approval
Lurbinectedin is under clinical development by Jazz Pharmaceuticals and currently in Phase II for Human Epidermal Growth Factor Receptor 2...
Lurbinectedin by Jazz Pharmaceuticals for Esophageal Cancer: Likelihood of Approval
Lurbinectedin is under clinical development by Jazz Pharmaceuticals and currently in Phase II for Esophageal Cancer. According to GlobalData, Phase...
Lurbinectedin by Jazz Pharmaceuticals for Metastatic Transitional (Urothelial) Tract Cancer: Likelihood of Approval
Lurbinectedin is under clinical development by Jazz Pharmaceuticals and currently in Phase II for Metastatic Transitional (Urothelial) Tract Cancer. According...
Lurbinectedin by Jazz Pharmaceuticals for Metastatic Biliary Tract Cancer: Likelihood of Approval
Lurbinectedin is under clinical development by Jazz Pharmaceuticals and currently in Phase II for Metastatic Biliary Tract Cancer. According to...
Lurbinectedin by Pharma Mar for Leiomyosarcoma: Likelihood of Approval
Lurbinectedin is under clinical development by Pharma Mar and currently in Phase III for Leiomyosarcoma. According to GlobalData, Phase III...